Junji Kawashima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junji Kawashima has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Eiichi Araki
Department of Metabolic Medicine, Faculty of Life Sciences Kumamoto University Kumamoto Japan
9 shared publications - Tatsuya Kondo
Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
6 shared publications - Daisuke Kukidome
Faculty of Life Sciences, Department of Metabolic Medicine, Kumamoto University, Kumamoto, Japan
3 shared publications Hiroyuki Motoshima
3 shared publications- Nobuhiro Miyamura
Department of Metabolic Medicine, Kumamoto University School of Medicine, Japan
3 shared publications - Sayaka Kitano
Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
3 shared publications
Latest Publications
- Open Access
- 14 May 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (5) , 674
Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets
Because the renin-angiotensin-aldosterone system influences glucose homeostasis, the mineralocorticoid receptor (MR) signal in pancreatic islets may regulate insulin response upon glucose load. Glucagon-like peptide-1 (GLP-1) production is stimulated by interleukin-6 (IL-6) in pancreatic α-cells. To determine how glucose homeostasis is regulated by interactions of MR, IL-6 and GLP-1 in islets, we performed glucose tolerance and histological analysis of islets in primary aldosteronism (PA) model rodents and conducted in vitro experiments using α-cell lines. We measured active GLP-1 concentration in primary aldosteronism (PA) patients before and after the administration of MR antagonist eplerenone. In PA model rodents, aldosterone decreased insulin-secretion and the islet/pancreas area ratio and eplerenone added on aldosterone (E+A) restored those with induction of IL-6 in α-cells. In α-cells treated with E+A, IL-6 and GLP-1 concentrations were increased, and anti-apoptotic signals were enhanced. The E+A-treatment also significantly increased MR and IL-6 mRNA and these upregulations were blunted by MR silencing using small interfering RNA (siRNA). Transcriptional activation of the IL-6 gene promoter by E+A-treatment required an intact MR binding element in the promoter. Active GLP-1 concentration was significantly increased in PA patients after eplerenone treatment. MR signal in α-cells may stimulate IL-6 production and increase GLP-1 secretion, thus protecting pancreatic β-cells and improving glucose homeostasis.
- 14 May 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (5) , 674
Open AccessMineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets
Because the renin-angiotensin-aldosterone system influences glucose homeostasis, the mineralocorticoid receptor (MR) signal in pancreatic islets may regulate insulin response upon glucose load. Glucagon-like peptide-1 (GLP-1) production is stimulated by interleukin-6 (IL-6) in pancreatic α-cells. To determine how glucose homeostasis is regulated by interactions of MR, IL-6 and GLP-1 in islets, we performed glucose tolerance and histological analysis of islets in primary aldosteronism (PA) model rodents and conducted in vitro experiments using α-cell lines. We measured active GLP-1 concentration in primary aldosteronism (PA) patients before and after the administration of MR antagonist eplerenone. In PA model rodents, aldosterone decreased insulin-secretion and the islet/pancreas area ratio and eplerenone added on aldosterone (E+A) restored those with induction of IL-6 in α-cells. In α-cells treated with E+A, IL-6 and GLP-1 concentrations were increased, and anti-apoptotic signals were enhanced. The E+A-treatment also significantly increased MR and IL-6 mRNA and these upregulations were blunted by MR silencing using small interfering RNA (siRNA). Transcriptional activation of the IL-6 gene promoter by E+A-treatment required an intact MR binding element in the promoter. Active GLP-1 concentration was significantly increased in PA patients after eplerenone treatment. MR signal in α-cells may stimulate IL-6 production and increase GLP-1 secretion, thus protecting pancreatic β-cells and improving glucose homeostasis.
- Open Access
- 30 January 2018
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 18 (1) , 4
The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report
Gestational diabetes insipidus (GDI) is a rare endocrine complication during pregnancy that is associated with vasopressinase overproduction from the placenta. Although increased vasopressinase is associated with placental volume, the regulation of placental growth in the later stage of pregnancy is not well known. A 16-year-old pregnant woman was urgently transferred to our hospital because of threatened premature labor when the Kumamoto earthquakes hit the area where she lived. During her hospitalization, she complained of gradually increasing symptoms of polyuria and polydipsia. The serum level of arginine vasopressin (AVP) was 1.7 pg/mL, which is inconsistent with central DI. The challenge of diagnostic treatment using oral 1-deamino-8-D-AVP (DDAVP) successfully controlled her urine and allowed for normal delivery. DDAVP tablets were not necessary to control her polyuria thereafter. Based on these observations, clinical diagnosis of GDI was confirmed. Pathophysiological analyses revealed that vasopressinase expression was more abundant in the GDI patient’s syncytiotrophoblast in placenta compared with that in a control subject. Serum vasopressinase was also observed during gestation and disappeared soon after delivery. Vasopressinase is reportedly identical to oxytocinase or insulin regulated aminopeptidase (IRAP), which is an abundant cargo protein associated with the glucose transporter 4 (GLUT4) storage vesicle. Interestingly, the expression and subcellular localization of GLUT4 appeared to occur in a vasopressinase (IRAP)-dependent manner. Because placental volume may be associated with vasopressinase overproduction in GDI, vasopressinase (IRAP)/GLUT4 association appears to contribute to the growth of placenta in this case.
- 30 January 2018
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 18 (1) , 4
Open AccessThe clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report
Gestational diabetes insipidus (GDI) is a rare endocrine complication during pregnancy that is associated with vasopressinase overproduction from the placenta. Although increased vasopressinase is associated with placental volume, the regulation of placental growth in the later stage of pregnancy is not well known. A 16-year-old pregnant woman was urgently transferred to our hospital because of threatened premature labor when the Kumamoto earthquakes hit the area where she lived. During her hospitalization, she complained of gradually increasing symptoms of polyuria and polydipsia. The serum level of arginine vasopressin (AVP) was 1.7 pg/mL, which is inconsistent with central DI. The challenge of diagnostic treatment using oral 1-deamino-8-D-AVP (DDAVP) successfully controlled her urine and allowed for normal delivery. DDAVP tablets were not necessary to control her polyuria thereafter. Based on these observations, clinical diagnosis of GDI was confirmed. Pathophysiological analyses revealed that vasopressinase expression was more abundant in the GDI patient’s syncytiotrophoblast in placenta compared with that in a control subject. Serum vasopressinase was also observed during gestation and disappeared soon after delivery. Vasopressinase is reportedly identical to oxytocinase or insulin regulated aminopeptidase (IRAP), which is an abundant cargo protein associated with the glucose transporter 4 (GLUT4) storage vesicle. Interestingly, the expression and subcellular localization of GLUT4 appeared to occur in a vasopressinase (IRAP)-dependent manner. Because placental volume may be associated with vasopressinase overproduction in GDI, vasopressinase (IRAP)/GLUT4 association appears to contribute to the growth of placenta in this case.
- 1 August 2017
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 31 (8) , 1275-1282
Impaired balance is related to the progression of diabetic complications in both young and older adults
- 1 August 2017
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 31 (8) , 1275-1282
Impaired balance is related to the progression of diabetic complications in both young and older adults
- Open Access
- 4 November 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 160
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors modulate incretin hormones and exert anti-diabetic effects in type 2 diabetes mellitus. Treatment with angiotensin II type 1 receptor blockers (ARB) is a proven successful intervention for hypertension with type 2 diabetes. The present study investigated the combined effects of the DPP-4 inhibitor vildagliptin and the ARB valsartan in a mouse model of type 2 diabetes. Methods: C57BL/6 J mice fed with high-fat diet (HFD) or db/db mice were treated with placebo, phloridzin (PHZ), vildagliptin alone (ViL), valsartan alone (VaL) or ViL with VaL (ViLVaL) for 8 weeks. Results: Glucose metabolism was improved in response to PHZ, ViL and ViLVaL in both HFD and db/db mice. Upon glucose challenge, ViLVaL showed the greatest suppression of blood glucose excursions, with increased insulin secretion, in db/db mice. ViLVaL treatment also showed an improvement of insulin sensitivity in db/db mice. Serum inflammatory cytokines were significantly decreased, and adiponectin was highest, in the ViLVaL group. ViLVaL improved insulin signaling and attenuated stress signaling in liver with amelioration of hepatic steatosis due to activated fatty acid oxidation in db/db mice. Furthermore, immunohistochemical analysis of the pancreas revealed that the combination treatment resulted in an increased expression of insulin and PDX-1, and increased insulin content. Conclusions: The combination therapy of ViL and VaL improves both pancreatic beta-cell function and insulin sensitivity, with a reduction of the inflammatory and cell stress milieu in mouse models of T2DM. Our results suggest that this combination therapy exerts additive or even synergistic benefits to treat T2DM.
- 4 November 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 160
Open AccessEffects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors modulate incretin hormones and exert anti-diabetic effects in type 2 diabetes mellitus. Treatment with angiotensin II type 1 receptor blockers (ARB) is a proven successful intervention for hypertension with type 2 diabetes. The present study investigated the combined effects of the DPP-4 inhibitor vildagliptin and the ARB valsartan in a mouse model of type 2 diabetes. Methods: C57BL/6 J mice fed with high-fat diet (HFD) or db/db mice were treated with placebo, phloridzin (PHZ), vildagliptin alone (ViL), valsartan alone (VaL) or ViL with VaL (ViLVaL) for 8 weeks. Results: Glucose metabolism was improved in response to PHZ, ViL and ViLVaL in both HFD and db/db mice. Upon glucose challenge, ViLVaL showed the greatest suppression of blood glucose excursions, with increased insulin secretion, in db/db mice. ViLVaL treatment also showed an improvement of insulin sensitivity in db/db mice. Serum inflammatory cytokines were significantly decreased, and adiponectin was highest, in the ViLVaL group. ViLVaL improved insulin signaling and attenuated stress signaling in liver with amelioration of hepatic steatosis due to activated fatty acid oxidation in db/db mice. Furthermore, immunohistochemical analysis of the pancreas revealed that the combination treatment resulted in an increased expression of insulin and PDX-1, and increased insulin content. Conclusions: The combination therapy of ViL and VaL improves both pancreatic beta-cell function and insulin sensitivity, with a reduction of the inflammatory and cell stress milieu in mouse models of T2DM. Our results suggest that this combination therapy exerts additive or even synergistic benefits to treat T2DM.
- 1 June 2011
- Published by The Endocrine Society
- p. P1-237
Two Cases with Metastatic Calcification in Parathyroid Carcinoma
- 1 June 2011
- Published by The Endocrine Society
- p. P1-237
Two Cases with Metastatic Calcification in Parathyroid Carcinoma
- 1 June 2011
- Published by The Endocrine Society
- p. P2-603
A New Cost-Effective Method for Screening and Diagnosing Primary Aldosteronism
Primary aldosteronism (PA) is the most common disorder that represents the secondary hypertension. The case detection test (CDT), further confirmatory test (FCT), and subtype evaluation are of particular importance for selecting an appropriate treatment strategy of the disease. The plasma aldosterone to renin activity ratio (ARR) is used as the standard CDT with following FCT. When confirmed, adrenal vein sampling (AVS) is currently the best reliable method to localize the responsible lesions. The major remaining problem is how to select or restrict AVS test recipients because of its cost, invasiveness, and requirements of highly experienced radiologists. Accordingly, FCT should be as definitive as possible; however, current methods of FCT may be time consuming, expensive, or demanding for physical stresses of the examinees. Therefore, we evaluated a new method using a combination of ARR and ACTH (cosyntropin) loading test as another CDT and/or FCT. Consecutive 114 patients including those who were referred to our hospital because of 1) suspicion for PA having classical manifestations such as hypertension with hypokalemia, 2) PA-detecting purpose in hypertensive patients without typical manifestations of PA, and 3) further examinations for mostly incidentally identified adrenal tumor(s), were examined. ARR measurement and ACTH (cosyntropin) loading test measuring maximum value of aldosterone to cortisol ratio induced by ACTH loading (MaxACR) were performed in all 114 cases. Final diagnosis of PA (n=53) was based on 1) AVS results and pathological data in unilateral cases, 2) AVS results in bilateral or un-operated cases, or 3) biochemical confirmatory data in cases where AVS was unsuccessful or not performed.
- 1 June 2011
- Published by The Endocrine Society
- p. P2-603
A New Cost-Effective Method for Screening and Diagnosing Primary Aldosteronism
Primary aldosteronism (PA) is the most common disorder that represents the secondary hypertension. The case detection test (CDT), further confirmatory test (FCT), and subtype evaluation are of particular importance for selecting an appropriate treatment strategy of the disease. The plasma aldosterone to renin activity ratio (ARR) is used as the standard CDT with following FCT. When confirmed, adrenal vein sampling (AVS) is currently the best reliable method to localize the responsible lesions. The major remaining problem is how to select or restrict AVS test recipients because of its cost, invasiveness, and requirements of highly experienced radiologists. Accordingly, FCT should be as definitive as possible; however, current methods of FCT may be time consuming, expensive, or demanding for physical stresses of the examinees. Therefore, we evaluated a new method using a combination of ARR and ACTH (cosyntropin) loading test as another CDT and/or FCT. Consecutive 114 patients including those who were referred to our hospital because of 1) suspicion for PA having classical manifestations such as hypertension with hypokalemia, 2) PA-detecting purpose in hypertensive patients without typical manifestations of PA, and 3) further examinations for mostly incidentally identified adrenal tumor(s), were examined. ARR measurement and ACTH (cosyntropin) loading test measuring maximum value of aldosterone to cortisol ratio induced by ACTH loading (MaxACR) were performed in all 114 cases. Final diagnosis of PA (n=53) was based on 1) AVS results and pathological data in unilateral cases, 2) AVS results in bilateral or un-operated cases, or 3) biochemical confirmatory data in cases where AVS was unsuccessful or not performed.
- 1 June 2011
- Published by The Endocrine Society
- p. P2-647
Usefulness of the ACTH Administration Test in Three Cases with Hypercortisolism and Hyperaldosteronism
Comorbidity of two adrenal disorders in a patient, hyperaldosteronism (HA) and hypercortisolism (HC), should not be overlooked to select an optimal treatment strategy for the patient, and HA in such cases tends to be masked by low ACTH levels induced by HC. We report herein three cases in which the ACTH administration test was useful to find the complications.
- 1 June 2011
- Published by The Endocrine Society
- p. P2-647
Usefulness of the ACTH Administration Test in Three Cases with Hypercortisolism and Hyperaldosteronism
Comorbidity of two adrenal disorders in a patient, hyperaldosteronism (HA) and hypercortisolism (HC), should not be overlooked to select an optimal treatment strategy for the patient, and HA in such cases tends to be masked by low ACTH levels induced by HC. We report herein three cases in which the ACTH administration test was useful to find the complications.
- 1 June 2011
- Published by The Endocrine Society
- p. P2-517
Activation of Heat Shock Response Reduces Visceral Adiposity, Improves Insulin Resistance and Inflammatory Markers in Male Subjects with Metabolic Syndrome and Type 2 Diabetes
Reduction of heat shock protein (Hsp) 72 is associated with insulin resistance and chronic inflammation, because Hsp72 is regulated by GSK-3β and is also a natural inhibitor of JNK and ASK1. Induction of Hsp72 improves glucose intolerance and insulin sensitivity, and reduces visceral adiposity in diabetic model mice (1). However, its impact on human with metabolic syndrome (MS) or type 2 diabetes (T2DM) is unknown. Forty male subjects with MS or 40 of those with T2DM were randomly assigned into 2 groups, respectively. One group was treated with MET (Mild Electrical stimulation with Thermo: 12V, 55 pulses per second, 60 min at 42oC, 4 times a week) for 12 weeks followed by 12 weeks of non-treatment. The order was reversed in the other group. MET treatment did not induce any unfavorable effects nor muscle contraction/pain. In MS subjects, visceral adipose volume measured by abdominal CT scan was significantly decreased by 5.79 ± 0.36% (p=0.00079) and waist circumference was also reduced by 0.70 ± 0.08% (p=0.017), whereas body weight and subcutaneous adipose volume were not. Both systolic and diastolic blood pressure were significantly reduced by 4.19 ± 0.27% (p=0.0039) and 2.7 ± 0.28% (p=0.033), respectively. Fasting plasma glucose and insulin levels were both decreased by 4.87 ± 0.33% (p=0.0035) and 8.49 ± 0.91% (p=0.015), respectively. HbA1c showed a trend of reduction, but could not reach statistical significance (-1.19 ± 0.14%, p=0.065). HOMA-IR, QUICKI and composite WBISI were all significantly improved by -11.7 ± 1.0% (p=0.0048), +2.44 ± 0.18% (p=0.0046) and +17.2 ± 1.0% (p=0.0014), respectively, while insulinogenic index (I.I.) was significantly decreased by 10.2 ± 2.0% (p=0.041). Inflammatory cytokines or adipokines, such as hs-CRP, adiponectin, leptin and TNF-α were all improved by -27.4 ± 5.9% (p=0.028), +9.3 ± 1.1% (p=0.035), -8.27 ± 0.87% (p=0.022) and -10.22 ± 1.00% (p=0.044), respectively. In addition, WBC and LDL-C were decreased by 5.38 ± 0.56% (p=0.028) and 5.26 ± 0.37% (p=0.005), respectively. An interim report of T2DM trial indicated similar results as in MS so far. MET treatment improved glucose homeostasis and insulin resistance in males with MS or T2DM. Reduction of insulin secreting capacity in MS suggested by reduced I.I. may protect pancreatic β-cells from overproduction of insulin. In addition, significant reductions in inflammatory cytokines, WBC and LDL-C suggest that MET also prevent atherogenic complications. (1) Morino S, Kondo T et al., PLoS ONE 2008; 3(12): e4068 Nothing to Disclose: TK, RM, SK, KM, RG, MAS, JK, HM, NF, KT, HK, EA
- 1 June 2011
- Published by The Endocrine Society
- p. P2-517
Activation of Heat Shock Response Reduces Visceral Adiposity, Improves Insulin Resistance and Inflammatory Markers in Male Subjects with Metabolic Syndrome and Type 2 Diabetes
Reduction of heat shock protein (Hsp) 72 is associated with insulin resistance and chronic inflammation, because Hsp72 is regulated by GSK-3β and is also a natural inhibitor of JNK and ASK1. Induction of Hsp72 improves glucose intolerance and insulin sensitivity, and reduces visceral adiposity in diabetic model mice (1). However, its impact on human with metabolic syndrome (MS) or type 2 diabetes (T2DM) is unknown. Forty male subjects with MS or 40 of those with T2DM were randomly assigned into 2 groups, respectively. One group was treated with MET (Mild Electrical stimulation with Thermo: 12V, 55 pulses per second, 60 min at 42oC, 4 times a week) for 12 weeks followed by 12 weeks of non-treatment. The order was reversed in the other group. MET treatment did not induce any unfavorable effects nor muscle contraction/pain. In MS subjects, visceral adipose volume measured by abdominal CT scan was significantly decreased by 5.79 ± 0.36% (p=0.00079) and waist circumference was also reduced by 0.70 ± 0.08% (p=0.017), whereas body weight and subcutaneous adipose volume were not. Both systolic and diastolic blood pressure were significantly reduced by 4.19 ± 0.27% (p=0.0039) and 2.7 ± 0.28% (p=0.033), respectively. Fasting plasma glucose and insulin levels were both decreased by 4.87 ± 0.33% (p=0.0035) and 8.49 ± 0.91% (p=0.015), respectively. HbA1c showed a trend of reduction, but could not reach statistical significance (-1.19 ± 0.14%, p=0.065). HOMA-IR, QUICKI and composite WBISI were all significantly improved by -11.7 ± 1.0% (p=0.0048), +2.44 ± 0.18% (p=0.0046) and +17.2 ± 1.0% (p=0.0014), respectively, while insulinogenic index (I.I.) was significantly decreased by 10.2 ± 2.0% (p=0.041). Inflammatory cytokines or adipokines, such as hs-CRP, adiponectin, leptin and TNF-α were all improved by -27.4 ± 5.9% (p=0.028), +9.3 ± 1.1% (p=0.035), -8.27 ± 0.87% (p=0.022) and -10.22 ± 1.00% (p=0.044), respectively. In addition, WBC and LDL-C were decreased by 5.38 ± 0.56% (p=0.028) and 5.26 ± 0.37% (p=0.005), respectively. An interim report of T2DM trial indicated similar results as in MS so far. MET treatment improved glucose homeostasis and insulin resistance in males with MS or T2DM. Reduction of insulin secreting capacity in MS suggested by reduced I.I. may protect pancreatic β-cells from overproduction of insulin. In addition, significant reductions in inflammatory cytokines, WBC and LDL-C suggest that MET also prevent atherogenic complications. (1) Morino S, Kondo T et al., PLoS ONE 2008; 3(12): e4068 Nothing to Disclose: TK, RM, SK, KM, RG, MAS, JK, HM, NF, KT, HK, EA